The National Medical Products Administration of the government of China has announced that the Chinese government has approved three traditional Chinese medicine (TCM) products for sale to help treat COVID-19, CNN reported on Thursday.
The agency stated that it used a special approval procedure to green-light the three products, providing "more options" for COVID-19 treatment.
The statement said that these herbal products come in granular form and trace their origins to "ancient Chinese prescriptions", adding they were developed from TCM remedies that had been used early in the pandemic, and that were "screened by many academics and experts on the front line".
These three approved products are "lung-clearing and detoxing granules", "dampness-resolving and detoxing granules" and "lung-diffusing and detoxing granules".
According to CNN, the safety and effectiveness of TCM is still debated in China, where it has both supporters and sceptics.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review